| PDF (1MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-312384
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.31238
Zusammenfassung
The alkylating agent bendamustine is approved for the treatment of hematopoietic malignancies such as non-Hodgkin lymphoma, chronic lymphocytic leukemia and multiple myeloma. As preliminary data on recently disclosed bendamustine esters suggested increased cytotoxicity, we investigated representative derivatives in more detail. Especially basic esters, which are positively charged under ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik